KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Cash from Operations (2016 - 2025)

Novavax has reported Cash from Operations over the past 16 years, most recently at 39440000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 39440000.0 for Q4 2025, up 77.22% from a year ago — trailing twelve months through Dec 2025 was 244600000.0 (down 180.3% YoY), and the annual figure for FY2025 was 244600000.0, down 180.3%.
  • Cash from Operations for Q4 2025 was 39440000.0 at Novavax, down from 107840000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for NVAX hit a ceiling of 663085000.0 in Q1 2021 and a floor of 342408000.0 in Q4 2021.
  • Median Cash from Operations over the past 5 years was 122658000.0 (2022), compared with a mean of 56941050.0.
  • Peak annual rise in Cash from Operations hit 2969.26% in 2021, while the deepest fall reached 2087.83% in 2021.
  • Novavax's Cash from Operations stood at 342408000.0 in 2021, then soared by 65.59% to 117816000.0 in 2022, then plummeted by 50.05% to 176781000.0 in 2023, then increased by 2.05% to 173163000.0 in 2024, then surged by 77.22% to 39440000.0 in 2025.
  • The last three reported values for Cash from Operations were 39440000.0 (Q4 2025), 107840000.0 (Q3 2025), and 127500000.0 (Q2 2025) per Business Quant data.